| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.8 | 1.0 |
| Profit before tax | -95.6 | -59.7 |
| Net income | -95.6 | -59.7 |
| EPS (diluted, $ a share) | $-1.07 | $-0.85 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -21.7% |
|---|
10-Q filed with the SEC, NASDAQ: EYPT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
EyePoint, Inc.: key numbers
- Share price
- $0.3076Close, Nov 16
- Market cap
- $35M
- Shares outstanding
- 113.78MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Laboratory Analytical InstrumentsSIC 3826
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from EyePoint, Inc.
All →EyePoint Earnings Call: Key Takeaways
EyePoint is pivoting to Diabetic Macular Edema (DME) after Phase 3 Wet AMD trials failed, implementing a 53% workforce reduction to preserve cash.
- Call
- Nov 12, 2026, 8:30 AM ET
EyePoint Financial Results
EyePoint reported Q3 2026 financial results and announced a strategic prioritization of its DURAVYU Phase 3 program in Diabetic Macular Edema (DME). The company expects this prioritization to generate $30 million in annualized savings following mixed Phase 3 results in wet AMD.
“The recent Phase 3 wet AMD data demonstrated DURAVYU’s ability to control fluid and maintain retinal anatomy through Week 56, along with a favorable safety profile that included every six-month redosing. This important data supports our strategic decision to prioritize our resources on DME, where we believe there is strong scientific and clinical rationale for DURAVYU as a durable treatment option for this vision threatening exudative disease.”
Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint
EyePoint Business Update
EyePoint is implementing a strategic prioritization plan that includes a 53% workforce reduction and the early conclusion of its Phase 3 wet AMD clinical trials after the LUCIA study failed to meet its primary endpoint. The company will focus its remaining resources on the development of DURAVYU for diabetic macular edema (DME), expecting to save approximately $30 million annually while incurring $9 million in one-time restructuring charges.
EyePoint Clinical Trial Data
EyePoint announced topline results from LUCIA, its second pivotal Phase 3 clinical trial of DURAVYU for wet age-related macular degeneration (wet AMD). The trial failed to meet its primary endpoint of statistical non-inferiority in mean change in best corrected visual acuity (BCVA) compared to the aflibercept control, although it did meet secondary endpoints related to treatment burden reduction and safety.